StartX is an educational non-profit organization with the mission to accelerate the development of top entrepreneurs in the Stanford University network. “With the wealth of industry expertise in drug discovery and development coupled with relentless focus on execution, they will be achieving exciting new milestones while working with StartX.” “Immune-Onc is developing a strong portfolio of innovative immuno-oncology drugs with first-in-class potential,” said Dr. The Company, supported by strategic collaborations with leading investigators from Albert Einstein College of Medicine and University of Texas, among others, is building a promising pipeline of therapeutic antibodies targeting the tumor microenvironment. This is one of the world’s top startup accelerator programs conducted by StartX, a Stanford University-affiliated nonprofit organization.įounded in 2016, Immune-Onc is applying the latest scientific insights and extensive industry expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
(“Immune-Onc”), a new biopharmaceutical company focused on advancing immuno-oncology therapeutics, announced that StartX has selected the Company and its co-founders to participate in the StartX Med Accelerator Summer 2017 Program. PALO ALTO, CA, J/ Business Wire / - Immune-Onc Therapeutics, Inc.
0 kommentar(er)
